🌿 Curaleaf boosts bid for Aurora takeover, researchers explore THC anxiety triggers, and U.S. medical cannabis ecosystem evolves

Happy Friday Pre Rollers! Welcome to another edition of The Pre Roll, the cannabis newsletter that keeps you up-to-date on the industry happenings you need to know.

Here’s what we’re rolling up this week:

…and more. Let’s get to it.

Was this email forwarded to you?

Up the ante. Curaleaf has sweetened its unsolicited bid for Aurora Cannabis, raising the total consideration by 25% to $5.00 per Aurora share. The enhanced offer includes $1.00 in cash plus 0.4013 Curaleaf shares, representing an 86% premium to Aurora’s unaffected share price. Curaleaf also raised the offer’s maximum consideration to $6.00 per share.

Curaleaf says the combination would create a global cannabis company operating across 17 countries, with more than $1.5 billion in annual revenue and nearly $350 million in adjusted EBITDA. The company estimates at least $40 million in annual cost synergies and argues that combining Aurora’s international footprint and EU-GMP capabilities with Curaleaf’s U.S. platform would create a more diversified and scalable operator.

The higher bid comes as Curaleaf continues pressing Aurora’s board to engage in formal negotiations and provide customary due diligence access. Curaleaf says the enhanced proposal was developed using publicly available information and reflects feedback from Aurora shareholders. The transaction remains contested, making shareholder response and Aurora’s board decision key developments to watch as the takeover battle unfolds.

Break new ground. A new study is shedding light on why cannabis can sometimes produce anxiety, panic, and paranoia rather than relaxation. Researchers at Northwestern University studied mice given a synthetic cannabinoid that mimics THC and found that the animals showed stronger fear responses, particularly when exposed to a stressful threat.

The researchers traced the effect to a specific group of neurons in the brain’s central amygdala, a region involved in processing fear and anxiety. In mice, THC-like compounds seemed to turn down the brain’s natural “brakes,” allowing fear-related signals to become stronger. This made the animals more likely to react with anxiety and fear. When researchers blocked the activity of certain brain cells, those anxious behaviors were reduced.

For the cannabis industry, the findings offer a potential biological explanation for an experience consumers have long reported, while underscoring the complexity of THC’s effects. The study was conducted in mice, so researchers caution that the same mechanism has not yet been demonstrated in humans. Still, understanding the neural pathways behind cannabis-related anxiety could eventually inform more targeted approaches to preventing or treating adverse reactions.

On the rise. The United States now has nearly 4 million registered medical cannabis patients, according to new research published by the American College of Physicians. Patient enrollment has grown more than five-fold since 2016, when roughly 747,000 Americans were registered, although growth has flattened since 2022 as more states have adopted adult-use legalization.

Chronic pain remains by far the most common qualifying condition, reported by 65% of registered patients, followed by PTSD at 29% and anxiety at 17%. Researchers say the widespread use of medical cannabis underscores the need for continued clinical research into its potential benefits and risks, particularly for conditions where patients are already using cannabis therapeutically.

The medical cannabis ecosystem is also expanding in its number of providers with nearly 36,000 clinicians authorized to recommend cannabis in 2024, up from about 31,000 in 2020, while researchers identified close to 110,000 authorized caregivers.

California: A new law strengthens cannabis testing and quality control requirements by expanding retesting authority, allowing state off-the-shelf testing, requiring certificates of analysis upon consumer request, and imposing performance testing on cannabis laboratories.

Georgia: Georgia regulators approved home delivery of medical cannabis to registered patients, including those in long-term care, with deliveries expected to begin after an administrative process concludes in October.

Idaho: Voters will decide whether to amend the state Constitution to give the Legislature exclusive authority over legalizing cannabis, limiting the ability of voters to do so through ballot initiatives.

New York: The state’s regulated cannabis market continues to grow, with the Cannabis Control Board approving 14 new licenses, extending provisional licensing through 2028, opening a new cannabis nursery application window, and expanding support for social equity cultivators, as cumulative retail sales surpass $4.1 billion.

North Carolina: The state’s Advisory Council on Cannabis is considering a framework that would broadly prohibit public THC consumption, bar dedicated consumption lounges, potentially allow regulated THC beverages at restaurants, and impose civil fines for violations, with recommendations due to Governor Josh Stein by the end of the year.

Ohio: New recreational cannabis rules cap THC levels and package sizes across cannabis products.

Tennessee: Lawmakers are considering a tightly regulated medical cannabis program for certain serious conditions, despite strong opposition from the Tennessee Bureau of Investigation, whose claims that cannabis fuels crime drew skepticism from legislators.

Vireo Growth grabs fresh financing

The multi-state cannabis operator secured a $60 million real estate loan at 8.5% interest through 2034, using $49 million to refinance debt tied to its New York facility and $11 million to acquire a Florida cultivation facility.

Innovative Industrial Properties prepares preferred offering

The cannabis real estate investment trust has launched an offering of Series B cumulative redeemable preferred stock, with proceeds primarily intended to fund its $270 million life science investment commitment and other corporate investments.

Looking to get your business or brand in front of cannabis enthusiasts, entrepreneurs, and executives?

Email us here to learn more!

Stay tuned for more cannabis industry news next week!

💚,

The Pre Roll Team

*Did someone forward you this newsletter? Sign up here.